Английская Википедия:GNF6702

Материал из Онлайн справочника
Версия от 23:08, 10 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Drugbox | IUPAC_name = N-[4-fluoro-3-(6-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide | image = GNF6702_structure.png <!--Clinical data--> | tradename = | legal_US = | legal_status = <!--Pharmacokinetic data--> | bioavailability = | metabolism = | elimination_half-life = | excretion = <!--Ide...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

GNF6702 is the name for a broad-spectrum antiprotozoal drug invented by researchers working at the Genomics Institute of the Novartis Research Foundation in 2013,[1] with activity against leishmaniasis, Chagas disease and sleeping sickness. These three diseases are caused by related kinetoplastid parasites, which share similar biology. GNF6702 acts as allosteric proteasome inhibitor which was effective against infection with any of the three protozoal diseases in mice, while having little evident toxicity to mammalian cells.[2]

See also

References

Шаблон:Reflist

Шаблон:Excavata antiparasitics


Шаблон:Antimicrobial-stub